Investor Presentaiton

Key Business Performance RemsimaⓇ & InflectraⓇ As the most prescribed Infliximab drug, RemsimaⓇ has steady market share uptake after launching RemsimaⓇ SC in Europe & continuously expanding prescription in Japan & LATAM ✓ In the US, the market share uptake continued by accelerating prescription after additional listings at major US payers M/S of RemsimaⓇ in Europe and Japan M/S of InflectraⓇ in the US 46% 60% 59% 57% 56% 55% 54% 52% 53% 53% 52% 20% 20% 21% 18% 14% 11% 9% 8% 7% 6% 4% 17.2Q 4Q 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 21.2Q 4Q 22.2Q Europe Note: The market share is based on volume Source: IQVIA Japan 23% 32% 12% 9% 9% 8% 6% 7% 6% 4% 3% 1% 0% '18 '19 '20 Inflectra® Note: The market share is based on volume Source: Symphony Health A Biosimilar '21 '22.09 B Biosimilar Investor Relations 2022 8

View entire presentation